, Volume 65, Issue 9, pp 1207–1222 | Cite as

Pharmacological Management of Acute Agitation

  • John BattagliaEmail author
Therapy in Practice


Acute agitation occurs in a variety of medical and psychiatric conditions, and when severe can result in behavioural dyscontrol. Rapid tranquillisation is the assertive use of medication to calm severely agitated patients quickly, decrease dangerous behaviour and allow treatment of the underlying condition. Intramuscular injections of typical antipsychotics and benzodiazepines, given alone or in combination, have been the treatment of choice over the past few decades.

Haloperidol and lorazepam are the most widely used agents for acute agitation, are effective in a wide diagnostic arena and can be used in medically compromised patients. Haloperidol can cause significant extrapyramidal symptoms, and has rarely been associated with cardiac arrhythmia and sudden death. Lorazepam can cause ataxia, sedation and has additive effects with other CNS depressant drugs.

Recently, two fast-acting preparations of atypical antipsychotics, intramuscular ziprasidone and intramuscular olanzapine, have been developed for treatment of acute agitation. Intramuscular ziprasidone has shown significant calming effects emerging 30 minutes after administration for acutely agitated patients with schizophrenia and other nonspecific psychotic conditions. Intramuscular ziprasidone is well tolerated and has gained widespread use in psychiatric emergency services since its introduction in 2002. In comparison with other atypical antipsychotics, ziprasidone has a relatively greater propensity to increase the corrected QT (QTc) interval and, therefore, should not be used in patients with known QTc interval-associated conditions. Intramuscular olanzapine has shown faster onset of action, greater efficacy and fewer adverse effects than haloperidol or lorazepam in the treatment of acute agitation associated with schizophrenia, schizoaffective disorder, bipolar mania and dementia. Intramuscular olanzapine has been shown to have distinct calming versus nonspecific sedative effects. The recent reports of adverse events (including eight fatalities) associated with intramuscular olanzapine underscores the need to follow strict prescribing guidelines and avoid simultaneous use with other CNS depressants. Both intramuscular ziprasidone and intramuscular olanzapine have shown ease of transition to same-agent oral therapy once the episode of acute agitation has diminished. No randomised, controlled studies have examined either agent in patients with severe agitation, drug-induced states or significant medical comorbidity. Current clinical experience and one naturalistic study with intramuscular ziprasidone suggest that it is efficacious and can be safely used in such populations. These intramuscular atypical antipsychotics may represent a historical advance in the treatment of acute agitation.


Haloperidol Risperidone Olanzapine Ziprasidone Droperidol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in preparation of this manuscript. The author has served as a consultant and speaker for Eli Lilly & Co. and Pfizer Inc. Pharmaceuticals. The author would like to thank Dr Arthur Walaszek for his review of this manuscript.


  1. 1.
    Mendelowitz AJ. Assessment and treatment of acute psychotic agitation in an emergency room setting. Essent Psychopharmacol 2002; 5(1): 31–43Google Scholar
  2. 2.
    Citrome L, Volavka J. Violent patients in the emergency setting. Psychiatr Clin North Am 1999 Dec; 22(4): 789–801PubMedCrossRefGoogle Scholar
  3. 3.
    Elbogen EB, Tomkins AJ, Pothuloori AP, et al. Documentation of violence risk information in psychiatric hospital patient charts: an empirical examination. J Am Acad Psychiatry Law 2003; 31(1): 58–64PubMedGoogle Scholar
  4. 4.
    Soliman AE, Reza H. Risk factors and correlates of violence among acutely ill adult psychiatric inpatients. Psychiatr Serv 2001 Jan; 52(1): 75–80PubMedCrossRefGoogle Scholar
  5. 5.
    Lindenmayer JP. The pathophysiology of agitation. J Clin Psychiatry 2000; 61 Suppl. 14: 5–10PubMedGoogle Scholar
  6. 6.
    Citrome L, Nolan KA, Volavka J. Science-based treatment of aggression and agitation. In: Fishbein DH, editor. The science, treatment and prevention of antisocial behaviors: evidence-based practice. Kingston (NJ): Civic Research Institute, Inc., 2004Google Scholar
  7. 7.
    Van Kamman DP. Gamma-aminobutyric acid and the dopamine hypothesis of schizophrenia. Am J Psychiatry 1977 Feb; 134: 138–43Google Scholar
  8. 8.
    Steiniger B, Kretschmer BD. Glutamate and GABA modulate dopamine in the pedunculopontine tegmental nucleus. Exp Brain Res 2003 Apr; 149: 422–30PubMedGoogle Scholar
  9. 9.
    Mason AS, Granacher RP. Clinical handbook of antipsychotic drug therapy. New York: Brunner/Mazel, 1980Google Scholar
  10. 10.
    Nilsen JA. Immediate treatment expedites hospital release. Hosp Community Psychiatry 1969 Jan; 20: 36–8Google Scholar
  11. 11.
    Oldham AJ, Bott M. The management of excitement in a general hospital psychiatric ward by high dosage haloperidol. Acta Psychiatr Scand 1971; 47: 369–76PubMedCrossRefGoogle Scholar
  12. 12.
    Battaglia J, Lindborg SR, Alaka K, et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003; 21: 192–8PubMedCrossRefGoogle Scholar
  13. 13.
    Huf G, Coutinho ES, Adams CE, et al. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomized trial of midazolam versus haloperidol plus promethazine. TREC Collaborative Group. BMJ 2003 Sep 27; 327: 1–6Google Scholar
  14. 14.
    Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003 Dec; 60(12): 1228–35PubMedCrossRefGoogle Scholar
  15. 15.
    Leonard BE. Fundamentals of psychopharmacology. Chichester: Wiley & Sons, 1992Google Scholar
  16. 16.
    Mountain HE. Crash tranquilization in a milieu therapy setting. J Fort Logan Mental Health Center 1963; 11: 42–4Google Scholar
  17. 17.
    Menuck M, Voineskos G. Rapid parenteral treatment of acute psychosis. Compr Psychiatry 1981 Jul/Aug; 22: 351–61PubMedCrossRefGoogle Scholar
  18. 18.
    Dubin WR, Waxman HM, Weiss KJ, et al. Rapid tranquilization: the efficacy of oral concentrate. J Clin Psychiatry 1985 Nov; 46: 475–8PubMedGoogle Scholar
  19. 19.
    Coffman JA, Nasrallah HA, Lyskowski J, et al. Clinical effectiveness of oral and parenteral rapid neuroleptization. J Clin Psychiatry 1987; 48: 20–4PubMedGoogle Scholar
  20. 20.
    American Hospital Formulary Service drug information. 28:16.08 —antipsychotics. Bethesda (MD): American Society of Health System Pharmacists, 2004Google Scholar
  21. 21.
    Baldessarini RJ, Cohen BM, Teicher MH, et al. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988 Jan; 45: 79–91PubMedCrossRefGoogle Scholar
  22. 22.
    Neborsky R, Janowsky D, Munson E, et al. Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Arch Gen Psychiatry 1981 Feb; 38: 195–9PubMedCrossRefGoogle Scholar
  23. 23.
    Ulrich S, Neuhof S, Braun V, et al. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiatry 1998; 31: 163–9PubMedCrossRefGoogle Scholar
  24. 24.
    Bartels M, Heide K, Mann K, et al. Treatment of akathisia with lorazepam: an open clinical trial. Pharmacopsychiatry 1987; 20: 51–3PubMedCrossRefGoogle Scholar
  25. 25.
    Baldessarini RJ. Chemotherapy in psychiatry: priniciples and practice. Rev ed. Cambridge (MA): Harvard University Press, 1985Google Scholar
  26. 26.
    Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 1997 May–Jun; 17: 531–37PubMedGoogle Scholar
  27. 27.
    Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, Torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774–82PubMedCrossRefGoogle Scholar
  28. 28.
    Lazarus A, Dubin WR, Jaffe RL. Rapid tranquilization with neuroleptic drugs: neurologic concerns. Clin Neuropharmacol 1989; 12: 303–11PubMedCrossRefGoogle Scholar
  29. 29.
    Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993 Jan; 77(1): 185–202PubMedGoogle Scholar
  30. 30.
    Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004 Apr; 65(4): 464–70PubMedCrossRefGoogle Scholar
  31. 31.
    American Hospital Formulary Service drug information. 28:24.92 — miscellaneous anxiolytics, sedatives, hypnotics. Bethesda (MD): American Society of Health System Pharmacists, 2004Google Scholar
  32. 32.
    Chambers RA, Druss BG. Droperidol: efficacy and side effects in psychiatric emergencies. J Clin Psychiatry 1999; 60: 664–7PubMedCrossRefGoogle Scholar
  33. 33.
    Leeuwen AM, Molders J, Sterkmans P, et al. Droperidol in acutely agitated patients. J Nerv Ment Dis 1977; 164: 280–3PubMedCrossRefGoogle Scholar
  34. 34.
    Resnick M, Burton BT. Droperidol vs. haloperidol in the initial management of acutely agitated patients. J Clin Psychiatry 1984; 45: 298–9PubMedGoogle Scholar
  35. 35.
    Szuba MP, Bergman KS, Baxter LR, et al. Safety and efficacy of high dose droperidol in agitated patients [letter]. J Clin Psychopharm 1992 April; 12: 144–6CrossRefGoogle Scholar
  36. 36.
    Stanislav SW, Childs A. Evaluating the usage of droperidol in acutely agitated persons with brain injury. Brain Inj 2000; 14: 261–5PubMedCrossRefGoogle Scholar
  37. 37.
    Thomas H, Schwartz E, Petrilli R. Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Ann Emerg Med 1992 April; 21: 407–13PubMedCrossRefGoogle Scholar
  38. 38.
    Lischke V, Behne M, Doelken P, et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994 Nov; 79(5): 983–6PubMedCrossRefGoogle Scholar
  39. 39.
    Chase PB, Biros MH. A retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population. Acad Emerg Med 2002; 9: 1402–10PubMedCrossRefGoogle Scholar
  40. 40.
    Shale JH, Shale CM, Mastin WD. A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. J Clin Psychiatry 2003 May; 64: 500–5PubMedCrossRefGoogle Scholar
  41. 41.
    Lundbeck. Schizophrenia [online]. Available from URL: [Accessed 2004 Aug 10]
  42. 42.
    Chakravarti SK, Muthu A, Muthu PK, et al. Zuclopenthixol acetate: single dose treatment for acutely disturbed psychotic patients. Curr Med Res Opin 1990; 12: 58–65PubMedCrossRefGoogle Scholar
  43. 43.
    Taymeeyapradit U, Kuasirikul S. Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients. J Med Assoc Thai 2002 Dec; 85: 1301–8PubMedGoogle Scholar
  44. 44.
    Fitzgerald P. Long-acting antipsychotic medication, restraint and treatment in the management of acute psychosis. Aust N Z J Psychiatry 1999; 33: 660–6PubMedCrossRefGoogle Scholar
  45. 45.
    Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 2000; 61 Suppl. 14: 11–20PubMedGoogle Scholar
  46. 46.
    Singhal RL, Rastogi RB, Lapierre YD. Diazepam potentiates the effect of neuroleptics on behavioral activity as well as dopamine and norepinephrine turnover: do benzodiazepines have antipsychotic potency? J Neural Transmission 1983; 56: 127–38CrossRefGoogle Scholar
  47. 47.
    Wassef AA, Dott SG, Harris A, et al. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol 1999 Jun; 19: 222–32PubMedCrossRefGoogle Scholar
  48. 48.
    Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991; 148: 714–26PubMedGoogle Scholar
  49. 49.
    Gaudreault P, Guay J, Thivierge RL, et al. Benzodiazepine poisoning: Clinical and pharmacological considerations and treatment. Drug Saf 1991 Jul–Aug; 6(4): 247–65PubMedCrossRefGoogle Scholar
  50. 50.
    Shorr RI, Robin DW. Rational use of benzodiazepines in the elderly. Drugs Aging 1994 Jan; 4(1): 9–20PubMedCrossRefGoogle Scholar
  51. 51.
    Dietch JT, Jennings RK. Aggressive dyscontrol in patients treated with benzodiazepines. J Clin Psychiatry 1988 May; 49: 184–8PubMedGoogle Scholar
  52. 52.
    Greenblatt DJ, Shader RI, Franke K, et al. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 1979 Jan; 68: 57–63PubMedCrossRefGoogle Scholar
  53. 53.
    Greenblatt DJ, Divoll M, Harmatz JS, et al. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci 1982 Feb; 71: 248–52PubMedCrossRefGoogle Scholar
  54. 54.
    Cohen S, Khan A, Johnson S. Pharmacological management of manic psychosis in an unlocked setting. J Clin Psychopharmacol 1987; 7: 261–4PubMedGoogle Scholar
  55. 55.
    Foster S, Kessel J, Berman ME, et al. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 1997; 12: 175–9PubMedCrossRefGoogle Scholar
  56. 56.
    Lenox RH, Newhouse PA, Creelman WL, et al. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psychiatry 1992; 53: 47–52PubMedGoogle Scholar
  57. 57.
    Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991; 52: 177–80PubMedGoogle Scholar
  58. 58.
    Modell JG. Further experience and observations with lorazepam in the management of behavioral agitation [letter]. J Clin Psychopharmacol 1986 Dec; 6: 385–7PubMedGoogle Scholar
  59. 59.
    Bird RD, Makela EH. Alcohol withdrawal: what is the benzodiazepine of choice? Ann Pharmacother 1994 Jan; 28(1): 67–71PubMedGoogle Scholar
  60. 60.
    Miller Jr WC, McCurdy L. A double-blind comparison of the efficacy and safety of lorazepam and diazepam in the treatment of the acute alcohol withdrawal syndrome. Clin Ther. 1984; 6(3): 364–71PubMedGoogle Scholar
  61. 61.
    Greenblatt DJ, Miller LG, Shader RI. Clonazepam pharmacokinetics, brain uptake, and receptor interactions. J Clin Psychiatry 1987; 48 Suppl. 10: 4–9PubMedGoogle Scholar
  62. 62.
    Crevoisier C, Delisle MC, Joseph I, et al. Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular, and oral administration to healthy volunteers. Eur Neurol 2003; 49: 173–7PubMedCrossRefGoogle Scholar
  63. 63.
    Chouinard G, Annable L, Turnier L, et al. A double-blind randomized clinical trial of rapid tranquilization with IM clonazepam and IM haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatry 1993 Nov; 38 Suppl. 4: 114–20Google Scholar
  64. 64.
    Benazzi F, Mazzoli M, Rossi E. Benzodiazepines and acute psychotic agitation [letter]. Can J Psychiatry 1992 Dec; 37: 732–3PubMedGoogle Scholar
  65. 65.
    Bradwejn J, Shriqui C, Koszycki D, et al. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol 1990; 10: 403–8PubMedCrossRefGoogle Scholar
  66. 66.
    Binder RL. Three case reports of behavioral disinhibition with clonazepam. Gen Hosp Psychiatry 1987; 9: 151–3PubMedCrossRefGoogle Scholar
  67. 67.
    Karson CN, Weinberger DR, Bigelow L, et al. Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial. Am J Psychiatry. 1982 Dec; 139(12): 1627–8PubMedGoogle Scholar
  68. 68.
    Greenblatt DJ, Raskin A. Benzodiazepines: new indications. Psychopharmacol Bull 1986; 22: 77–87PubMedGoogle Scholar
  69. 69.
    Lerner Y, Lwow E, Levitin A, et al. Acute high-dose parenteral haloperidol treatment of psychosis. Am J Psychiatry 1979 Aug; 136: 1061–4PubMedGoogle Scholar
  70. 70.
    Salzman C. Use of benzodiazepines to control disruptive behavior in inpatients. J Clin Psychiatry 1988 Dec; 49 Suppl. 12: 13–5PubMedGoogle Scholar
  71. 71.
    Wyant M, Diamond BI, O’Neal E, et al. The use of midazolam in acutely agitated psychiatric patients. Psychopharmacol Bull 1990; 26: 126–9PubMedGoogle Scholar
  72. 72.
    Medoza R, Djenderedjian AH, Adams J, et al. Midazolam in acute psychotic patients with hyperarousal. J Clin Psychiatry 1987; 48: 291–2Google Scholar
  73. 73.
    Dorevitch A, Katz N, Zemishiany Z, et al. Intramuscular flunitrazepam versus instramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry 1999; 156: 142–4PubMedGoogle Scholar
  74. 74.
    Garza-Trevino ES, Hollister LE, Overall JE, et al. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 1989; 146: 1598–601PubMedGoogle Scholar
  75. 75.
    Thornton WE, Thornton BP. Crisis psychopharmacology techniques. Dis Nerv Syst 1974; 35: 32–4PubMedGoogle Scholar
  76. 76.
    Barbee JG, Mancuso DM, Freed CR, et al. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry 1992; 149: 506–10PubMedGoogle Scholar
  77. 77.
    Busch FN, Miller FT, Weiden PJ. A comparison of two adjunctive treatment strategies in acute mania. J Clin Psychiatry 1989; 50: 453–5PubMedGoogle Scholar
  78. 78.
    Menza MA, Murray GB, Holmes VF, et al. Controlled study of extrapyramidal reactions in the management of delirious, medically ill patients: intravenous haloperidol versus intravenous haloperidol plus benzodiazepines. Heart Lung 1988 May; 17: 238–41PubMedGoogle Scholar
  79. 79.
    Salzman C, Green AI, Rodriguez-Villa F, et al. Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. Psychosomatics 1986 Jan; 27 Suppl. 1: 17–21PubMedCrossRefGoogle Scholar
  80. 80.
    Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15: 335–40PubMedCrossRefGoogle Scholar
  81. 81.
    Bieniek SA, Ownby RL, Penalver A, et al. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 1998; 18: 57–62PubMedGoogle Scholar
  82. 82.
    Bodkin JA. Emerging uses for high-potency benzodiazepines in psychotic disorders. J Clin Psychiatry 1990 May; 51 Suppl. 5: 41–6PubMedGoogle Scholar
  83. 83.
    Adams F, Fernandez F, Andersson BS. Emergency pharmacotherapy of delirium in the critically ill cancer patient. Psychosomatics 1986 Jan; 27 Suppl. 1: 33–7PubMedCrossRefGoogle Scholar
  84. 84.
    Battaglia J, Thornton L, Young C. Loxapine-lorazepam induced hypotension and stupor [letter]. J Clin Psychopharmacol 1989; 9: 227–8PubMedCrossRefGoogle Scholar
  85. 85.
    Cohen S, Khan A. Respiratory distress with use of lorazepam in mania [letter]. J Clin Psychopharmacol 1987; 7: 199–200PubMedCrossRefGoogle Scholar
  86. 86.
    Citrome L. Atypical antipsychotitcs for acute agitation. Postgrad Med 2002 Dec; 112: 85–96PubMedCrossRefGoogle Scholar
  87. 87.
    Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004; 18(13): 877–93PubMedCrossRefGoogle Scholar
  88. 88.
    Jann MW, Bunt RM. Switching antipsychotic drugs: a pharmacokinetic, pharmacodynamic, and practical perspective. Psychopharmacol Bull 2002; 36: 22–41PubMedGoogle Scholar
  89. 89.
    Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002 Mar; 14(1): 47–57PubMedGoogle Scholar
  90. 90.
    McGorry PD, Chanen A, McCarthy E, et al. Posttraumatic stress disorder following recent-onset psychosis: an unrecognized postpsychotic syndrome. J Nerv Ment Dis 1991 May; 179: 253–8PubMedCrossRefGoogle Scholar
  91. 91.
    Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001; 62: 153–7PubMedCrossRefGoogle Scholar
  92. 92.
    Currier GW, Chou JC, Feifel D, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004; 65: 386–94PubMedCrossRefGoogle Scholar
  93. 93.
    Brook S. Intramuscular ziprasidone: moving beyond the conventional in treatment of acute agitation in schizophrenia. J Clin Psychiatry 2003; 64 Suppl. 19: 13–8PubMedGoogle Scholar
  94. 94.
    Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular ziprasidone 20mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology 2001; 155: 128–34PubMedCrossRefGoogle Scholar
  95. 95.
    Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2mg versus 10 mg, in the short term management of agitated psychotic patients. J Clin Psychiatry 2001; 62: 12–8PubMedCrossRefGoogle Scholar
  96. 96.
    Brook S, Lucey JV, Gunn KP, et al. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry 2000; 61: 933–41PubMedCrossRefGoogle Scholar
  97. 97.
    Daniel DG, Zimbroff DL, Swift RH, et al. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol 2004; 19: 9–15PubMedCrossRefGoogle Scholar
  98. 98.
    Preval H, Klotz SG, Southard R, et al. Rapid-acting IM ziprasidone in the psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry 2005; 27: 140–4PubMedCrossRefGoogle Scholar
  99. 99.
    Battaglia J. Intramuscular olanzapine: treating acute agitation in psychosis and bipolar mania. Curr Psychiatry 2004 May; 3: 76–8Google Scholar
  100. 100.
    Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158: 1149–51PubMedCrossRefGoogle Scholar
  101. 101.
    Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59: 441–8PubMedCrossRefGoogle Scholar
  102. 102.
    Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacology 2001; 21: 389–97CrossRefGoogle Scholar
  103. 103.
    Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26: 494–504PubMedCrossRefGoogle Scholar
  104. 104.
    Lindborg SR, Beasley CM, Alaka K, et al. Effects of intramuscular olanzapine vs. haloperidol and placebo QTc intervals in acutely agitated patients. Psychiatry Res. 2001 Jul; 119(1–2): 113–23Google Scholar
  105. 105.
    Eli Lilly and Company Limited. Letter to healthcare professionals. Basingstoke, Hampshire, UK: Eli Lilly and Company Limited, 2004 SepGoogle Scholar
  106. 106.
    Wright P, Meehan K, Birkett M, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther 2003; 25: 1420–8PubMedCrossRefGoogle Scholar
  107. 107.
    Bergstrom RF, Mitchell M, Witcher J, et al. Rapid onset of absorption with olanzapine orally disintegrating tablets [poster]. American Psychiatric Association Annual Meeting; 2004 May 1–6; New YorkGoogle Scholar
  108. 108.
    Aijluni V, Amirsadri A, Haddad L, et al. The use of orally disintegrating olanzapine for the control of acute agitation in an urban emergency psychiatric center [poster]. American Psychiatric Association Institute on Psychiatric Services; 2003 Oct 29–Nov 2; BostonGoogle Scholar
  109. 109.
    Battaglia J. Is this patient dangerous? 5 steps to assess risk for violence. Current Psychiatry 2004 Feb; 3: 14–21Google Scholar
  110. 110.
    Alexopoulos GS, Streim J, Carpenter D, et al. Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65 Suppl. 2: 5–99PubMedGoogle Scholar
  111. 111.
    Levy WO, Robichaux-Keene NR, Nunez C. No significant QTc interval changes with high-dose ziprasidone: a case series. J Psychiatr Pract 2004; 10: 227–32PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Department of Psychiatry and Behavioural MedicineMedical College of WisconsinMilwaukeeUSA

Personalised recommendations